{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:49Z","timestamp":1790740609583,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.diabres.2024.111959","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T16:35:20Z","timestamp":1734107720000},"page":"111959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world safety of dapagliflozin plus metformin in patients of type 2 diabetes mellitus in China: Post-hoc analysis of the DONATE study"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-1798","authenticated-orcid":false,"given":"Lixin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-3544","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2024.111959_b0005","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966.","DOI":"10.1007\/s00125-022-05787-2"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.diabres.2024.111959_b0015","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/dom.12977","article-title":"Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy","volume":"19","author":"Owens","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2024.111959_b0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"issue":"12 Suppl","key":"10.1016\/j.diabres.2024.111959_b0025","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.4065\/mcp.2010.0471","article-title":"Defining and achieving treatment success in patients with type 2 diabetes mellitus","volume":"85","author":"Stolar","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"10.1016\/j.diabres.2024.111959_b0035","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pedi.12473","article-title":"Metformin; a review of its history and future: from lilac to longevity","volume":"18","author":"Thomas","year":"2017","journal-title":"Pediatr Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2024.111959_b0045","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc23-Sint","article-title":"Introduction and methodology: standards of care in diabetes","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2024.111959_b0050","unstructured":"Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020). Chinese J Diabetes Mellitus. 2021;13(4):315-409."},{"key":"10.1016\/j.diabres.2024.111959_b0055","unstructured":"Academic Committee of Metabolic Management Center, Expert Advisory Committee of Metabolic Management Center, Council of Metabolic Management Center. Metabolic disease management guideline for National Metabolic Management Center (2nd edition). Chin J Endocrinol Metab. 2023;39(06):538-554."},{"key":"10.1016\/j.diabres.2024.111959_b0060","unstructured":"Expert consensus on sodium-glucose cotransporter-2 inhibitors with metformin in patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2023;43(05):437-448."},{"key":"10.1016\/j.diabres.2024.111959_b0065","doi-asserted-by":"crossref","unstructured":"Tajima A, Tobe K, Eiki J-i, et al. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND). BMJ Open Diabetes Research & Care. 2022;10(6):e003032.","DOI":"10.1136\/bmjdrc-2022-003032"},{"issue":"7","key":"10.1016\/j.diabres.2024.111959_b0070","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2024.111959_b0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.diabres.2024.111959_b0080","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8501418","article-title":"Efficacy and renal safety of dapagliflozin in patients with type 2 diabetes mellitus also receiving metformin: a real-life experience","volume":"2018","author":"Scorsone","year":"2018","journal-title":"J Diabetes Res"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12916-023-02906-7","article-title":"A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE)","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1463-1326.2010.01314.x","article-title":"Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.diabres.2024.111959_b0100","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-013-0128-8","article-title":"Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"9733","key":"10.1016\/j.diabres.2024.111959_b0105","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2024.111959_b0110","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"J Diabetes"},{"issue":"10","key":"10.1016\/j.diabres.2024.111959_b0115","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2024.111959_b0120","doi-asserted-by":"crossref","unstructured":"Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract. 2020;159(1872-8227 (Electronic)):107946.","DOI":"10.1016\/j.diabres.2019.107946"},{"issue":"3","key":"10.1016\/j.diabres.2024.111959_b0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2024.111959_b0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2024.111959_b0135","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/dom.13258","article-title":"Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin","volume":"20","author":"Del Prato","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.diabres.2024.111959_b0140","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.2337\/dc15-0811","article-title":"Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes","volume":"38","author":"Matthaei","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/14656566.2016.1121235","article-title":"Combination therapy for type 2 diabetes: dapagliflozin plus metformin","volume":"17","author":"Tan","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.diabres.2024.111959_b0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3904\/kjim.2020.327","article-title":"Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus","volume":"36","author":"Choi","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.diabres.2024.111959_b0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.diabres.2024.111959_b0160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2024.111959_b0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"8 Suppl","key":"10.1016\/j.diabres.2024.111959_b0170","first-page":"S132","article-title":"A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes","volume":"24","author":"Huang","year":"2018","journal-title":"Am J Manag Care"},{"issue":"5","key":"10.1016\/j.diabres.2024.111959_b0175","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/03007995.2018.1551192","article-title":"Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes","volume":"35","author":"Nishimura","year":"2019","journal-title":"Curr Med Res Opin"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:55:54Z","timestamp":1740102954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724008696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"alternative-id":["S0168822724008696"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111959","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety of dapagliflozin plus metformin in patients of type 2 diabetes mellitus in China: Post-hoc analysis of the DONATE study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111959"}}